Literature DB >> 32562184

Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti‑TSHR immunoassay for Graves' disease: a Chinese multicenter study.

Xinqi Cheng1, Xiaofeng Chai2, Chaochao Ma1, Qiang Jia3, Honggang Zhao4, Zuoliang Dong5, Zuncheng Zhang4, Yingying Hu1, Ailing Song1, Guohua Yang1, Ling Qiu6, Xiaolan Lian7.   

Abstract

BACKGROUND: Both thyroid-stimulating immunoglobulins immunoassay (TSI IA) and thyrotrophin receptor antibody immunoassay (TRAb IA) are commonly used for the diagnosis of Graves' disease (GD). The aim of the present study was to compare the clinical diagnostic performance of these two methods.
METHODS: Sera were obtained from 1103 subjects presenting a variety of clinical conditions from three centers: 100 subjects with untreated GD, 200 with treated GD, 62 with autoimmune thyroid disease(AIT), 216 with other thyroid diseases (OTHER-T), 214 with non-thyroid autoimmune diseases (NTAD), 191 with other diseases (OD), and 120 healthy subjects (HS). Both TSI and TRAb IAs were performed for all 1013 serum samples. Bioassay was performed for 86 samples whose TSI results were inconsistent the TRAb assay results.
RESULTS: Comparing untreated GD patients with the control groups (AIT, NTAD, OTHER-T, OD, and HS) resulted in an area under the curve (AUC) of 0.992 for the TSI IA and 0.989 for the TRAb IA with no statistically significant difference observed between these AUC values (P = 0.2733). The best TSI CDP (clinical decision point) value was 0.42 IU/L. The differences in sensitivity (100% vs. 95%, P = 0.7991) and specificity (97.1% vs. 97.6%, P = 0.9426) between the TSI and TRAb IA were not statistically significant. TSI IA had a higher agreement with the TSI bioassay than TRAb IA.
CONCLUSION: The clinical diagnostic performance of the TSI IA for diagnosing Graves' disease was very similar to that of the TRAb IA. TSI IA can be used to diagnose GD in the Chinese.

Entities:  

Keywords:  Graves’ disease; Thyroid-stimulating immunoglobulin; thyroid-stimulating hormone receptor autoantibody

Year:  2020        PMID: 32562184     DOI: 10.1007/s12020-020-02386-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  4 in total

1.  The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves' disease.

Authors:  Yulin Zhou; Mengxi Zhou; Yicheng Qi; Weiqing Wang; Xinxin Chen; Shu Wang
Journal:  Ther Adv Endocrinol Metab       Date:  2021-09-28       Impact factor: 3.565

2.  Evaluation of analytic and clinical performance of two immunoassays for detecting thyroid-stimulating receptor antibody in the diagnosis of Graves' disease.

Authors:  Yao Hu; Jiajin Ni; Yi Cen; Buyue Zhang; Wenqing Wu; Wei Cheng; Mingying Huang; Ming Guan
Journal:  J Clin Lab Anal       Date:  2021-11-09       Impact factor: 2.352

3.  Differential Diagnosis of Thyrotoxicosis by Machine Learning Models with Laboratory Findings.

Authors:  Jinyoung Kim; Han-Sang Baek; Jeonghoon Ha; Mee Kyoung Kim; Hyuk-Sang Kwon; Ki-Ho Song; Dong-Jun Lim; Ki-Hyun Baek
Journal:  Diagnostics (Basel)       Date:  2022-06-15

4.  Clinical evaluation of an automated TSI bridge immunoassay in the diagnosis of Graves' disease and its relationship to the degree of hyperthyroidism.

Authors:  Tianqi Liu; Xiuying Zhang; Li Long; Lingli Zhou; Jing Chen; Meng Li; Ying Gao; Xianghai Zhou; Xueyao Han; Linong Ji
Journal:  BMC Endocr Disord       Date:  2022-08-31       Impact factor: 3.263

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.